Studies of the effects of NSAIDs on the small intestine of the horse have focused on ischaemic injury of the jejunum. This injury is encountered clinically in cases of strangulating lesions of the jejunum such as small intestinal volvulus or strangulation by a pedunculated lipoma (Gerard et al. 1999). It has been demonstrated that flunixin meglumine retards recovery of the mucosal barrier in ischaemic equine jejunum as determined by the ex vivo measurement of transepithelial electrical resistance (TER) and the mucosal-to-serosal flux of mannitol (Tomlinson and Blikslager 2005). A clinically relevant measurement of mucosal barrier function is the mucosal-to-serosal paracellular flux of LPS (Koenig et al. 2009). Importantly, treatment with flunixin meglumine results in increased mucosal permeability to LPS following ischaemic injury and an 18 h recovery period (Tomlinson and Blikslager 2004a; Cook et al. 2009a). Flunixin meglumine inhibits the increase in thromboxane B2 (TXB2) and prostaglandin E2 (PGE2) observed during recovery from ischaemic injury both in vitro and ex vivo (Tomlinson and Blikslager 2005; Cook et al. 2009a). When ischaemic-injured equine jejunum is treated with a combination of flunixin meglumine and the prostaglandin E1 (PGE1) analogue misoprostol, the inhibitory effect on the recovery of barrier function is prevented (Tomlinson and Blikslager 2005). Therefore, the inhibition of barrier function in ischaemic equine jejunum by flunixin meglumine is probably due to the inhibition of cyclooxygenase in the intestine.
Following ischaemic injury, chemoattractants are released resulting in neutrophil migration and infiltration of injured tissues. This neutrophil infiltration and degranulation causes further tissue damage through physical opening of paracellular spaces and the release of proteases, e.g. elastase (Blikslager et al. 2007). It has been shown in a porcine experimental model that mucosal neutrophil infiltration following ischaemic injury is detrimental to mucosal barrier function (Gayle et al. 2002). Treatment with flunixin meglumine results in an increase in mucosal neutrophil infiltration in ischaemic equine jejunum over an 18 h recovery period (Cook et al. 2009b). The reason for this increase in neutrophil infiltration and its significance in the inhibition of mucosal barrier function recovery in the horse is unclear.
Following the identification of the detrimental effect of flunixin meglumine on mucosal barrier function recovery, several studies have examined alternative medications. Etodolac is an NSAID that was studied in an ex vivo model of equine ischaemic intestinal injury; however, there was no significant difference between the effect of etodolac and flunixin meglumine on the recovery of barrier function (Tomlinson et al. 2004). A later study revealed that etodolac has a COX selectivity ratio of 4.32 and is therefore not a COX-2 selective inhibitor in the horse (Davis et al. 2007). This may explain the inhibition of barrier function recovery by etodolac. Another NSAID that has been shown to preferentially inhibit COX-2 in the dog is meloxicam, which has a COX selectivity of 10 in a whole blood model (Brideau et al. 2001). A similar experiment using an equine whole blood model revealed a significantly lower COX selectivity ratio of 3.8 (Beretta et al. 2005). When meloxicam was examined in a model of ischaemic injury and recovery, it was found that it did not inhibit the recovery of mucosal barrier function as measured by TER and mucosal-to-serosal passage of inulin (Little et al. 2007). This study did not find a significant effect of either flunixin meglumine or meloxicam on the passage of LPS through ischaemic-injured tissue (Little et al. 2007). Both meloxicam and flunixin meglumine were shown to increase the mucosal neutrophil infiltration (Little et al. 2007). In addition to the inhibition of COX enzyme activity, it is possible that meloxicam has a COX-independent anti-inflammatory mechanism of action (Little et al. 2007). This is demonstrated by reduced upregulation of COX-2 protein expression in response to ischaemic injury following treatment with meloxicam (Little et al. 2007). However, as meloxicam was shown to have an equal or greater effect than flunixin meglumine on post operative pain in this experimental study, and it did not inhibit the recovery of mucosal barrier function, it appears to be a suitable alternative to flunixin meglumine for the treatment of colic (Little et al. 2007). As the efficacy of meloxicam as an analgesic is based on an experimental study, further investigation of the clinical efficacy of meloxicam is warranted.
In an effort to reduce adverse gastrointestinal effects in human medicine, COX-2 selective drugs have been developed. These drugs are often referred to as coxibs, and are designed to be potent inhibitors of COX-2 while allowing normal production of prostaglandins by COX-1 at clinically relevant concentrations (Cronstein 2002). Deracoxib is a coxib that is available for use in veterinary medicine and has been shown to selectively inhibit COX-2 in the dog (Gierse et al. 2002). A study of the in vitro recovery of ischaemic-injured equine jejunum showed that deracoxib was similar to flunixin meglumine and inhibited the recovery of mucosal barrier function as measured by TER (Tomlinson and Blikslager 2005). However, unlike flunixin meglumine, deracoxib treatment did not result in a significant increase in the mucosal-to-serosal passage of mannitol (Tomlinson and Blikslager 2005). Furthermore, deracoxib inhibited the increase in PGE2 and 6-keto-PGF1α, a stable metabolite of PGI2, without inhibiting an increase in TXB2 suggesting a COX-1 sparing effect (Tomlinson and Blikslager 2005). As this was an in vitro study the effect of deracoxib on neutrophil infiltration was not determined. Therefore, deracoxib may offer an alternative to flunixin meglumine in cases of small intestinal ischaemic injury. However, the clinical use of deracoxib is currently severely limited by the lack of a suitable intravenous formulation licensed for use in the horse.
Although meloxicam and deracoxib appear to offer advantages over flunixin meglumine for the treatment of small intestinal ischaemic injury (Tomlinson and Blikslager 2005; Little et al. 2007), neither is currently available for equine use in the USA and only meloxicam is available for the treatment of colic in Europe. However, a coxib has been recently approved for the treatment of musculoskeletal pain in the horse. This NSAID, firocoxib, has been shown to be a highly selective inhibitor of COX-2 in the horse with a COX selectivity ratio of 265 (McCann et al. 2002). In a clinical study, firocoxib was not associated with an increased risk of adverse gastrointestinal effects in the dog (Steagall et al. 2007). In an ex vivo study of ischaemic injury and recovery, treatment with firocoxib did not inhibit mucosal barrier function as measured by TER (Cook et al. 2009a). In this study, flunixin meglumine, but not firocoxib, was again shown to increase the permeability of the mucosa to LPS (Cook et al. 2009a). In horses treated with flunixin meglumine or firoxoxib there was no significant increase in the plasma PGE2 during the recovery period, suggesting that both NSAIDs inhibit the action of COX-2 (Cook et al. 2009a). Only flunixin meglumine inhibited the increase in plasma TXB2, suggesting that firocoxib did not significantly inhibit the action of COX-1 (Cook et al. 2009a). The effect of firocoxib on mucosal neutrophil infiltration is currently unknown.
The role played by mucosal neutrophils in the inhibition of mucosal barrier function recovery in the horse is unclear. Several studies have shown that there is an increase in mucosal neutrophil infiltration of injured jejunum in horses treated with flunixin meglumine, which is associated with reduced barrier function (Tomlinson et al. 2004; Little et al. 2007; Cook et al. 2009a). In contrast, treatment with meloxicam resulted in increased neutrophil infiltration without inhibition of barrier function recovery (Little et al. 2007). However, a recent study examining the effect of lidocaine on ischaemic injury and recovery of the equine jejunum suggested a role of mucosal neutrophil infiltration in barrier function (Cook et al. 2009c). In this study, while treatment with flunixin meglumine inhibited the recovery of mucosal barrier function, a combination of flunixin meglumine and lidocaine did not (Cook et al. 2009c). Interestingly, treatment with lidocaine significantly inhibited the mucosal infiltration of neutrophils associated with flunixin meglumine treatment (Cook et al. 2009c). However, an in vitro study found that lidocaine does not inhibit the migration and adhesion of equine neutrophils (Cook et al. 2009b). It appears that lidocaine prevents the inhibition of barrier function recovery associated with flunixin meglumine by an anti-inflammatory mechanism that is currently unknown and is indicated for clinical use in equine patients with small intestinal injury.
The large intestine of the horse has developed to perform the functions necessary for hindgut fermentation including mixing, secretion and absorption (Argenzio et al. 1974b). Following mixing in the caecum, ingesta enters the ventral colon every 3–4 min. The right and left ventral regions of the large colon are succulated and contain a large volume of mixed ingesta for fermentation. While the ventral colon does secrete a significant volume of fluid, in the normal situation there is a net absorption of water and sodium chloride (Argenzio et al. 1974b). However, when the right ventral colon is examined in vitro, production of endogenous prostanoids causes inhibition of sodium absorption and stimulation of chloride secretion (Clarke and Argenzio 1990). The in vitro treatment of normal right ventral colon with flunixin meglumine inhibits this increased chloride secretion (Freeman et al. 1997). Exposure of right ventral colon to reactive oxygen intermediates resulted in an increase in chloride secretion, which was abolished by treatment with flunixin meglumine (Inoue et al. 2007). However, as this model did not result in tissue injury or changes in mucosal barrier function the effect of flunixin meglumine on the recovery of the right ventral colon is unknown (Inoue et al. 2007). Since the recovery of barrier function has been associated with the stimulation of chloride secretion (Blikslager et al. 1999) and flunixin meglumine inhibits secretion by the right ventral colon (Freeman et al. 1997), it may inhibit recovery from ischaemic injury. However, ischaemic injury of the right ventral colon has not yet been investigated.
Following the large, sacculated ventral colon, the large colon of the horse loses its sacculations and narrows at the pelvic flexure. Although studies of the right ventral colon suggest that flunixin meglumine would inhibit recovery of the colon from ischaemic injury (Freeman et al. 1997), a study of the pelvic flexure found that treatment with flunixin meglumine did not adversely affect the recovery of mucosal barrier function (Matyjaszek et al. 2009). However, several differences between the response of the pelvic flexure and jejunum to ischaemic injury were discovered. In contrast to the results of previous studies in the jejunum (Tomlinson et al. 2004; Little et al. 2007; Cook et al. 2009a), the transepithelial electrical resistance (TER) of colonic mucosa following injury and recovery was significantly lower than uninjured mucosa (Matyjaszek et al. 2009). This is an interesting finding as it suggests a significant difference in the physiological response of the jejunal and colonic epithelia to injury. In jejunal tissue, an 18 h recovery results in a transepithelial electrical resistance significantly greater than that of uninjured tissue and the process by which this occurs is significantly inhibited by flunixin meglumine (Tomlinson et al. 2004; Little et al. 2007; Cook et al. 2009a). In contrast, the transepithelial electrical resistance of colonic tissue remains significantly lower than control tissue after 18 h of recovery and no significant effect of flunixin meglumine has been shown, possibly as the recovery process inhibited by flunixin meglumine is not occurring in the colon (Matyjaszek et al. 2009). Also, treatment with flunixin meglumine did not increase mucosal permeability to mannitol (Matyjaszek et al. 2009). While injury and recovery resulted in neutrophil infiltration of the lamina propria, treatment with flunixin meglumine did not increase accumulation (Matyjaszek et al. 2009). The effect of ischaemic injury or flunixin meglumine on the transmucosal passage of LPS is unknown. Therefore, would it appear that there are significant differences in the responses of the equine jejunum and pelvic flexure to ischaemic injury and flunixin meglumine. These results suggest that the large colon will remain more permeable to intestinal contents, including LPS, for a period >18 h following ischaemic injury and that treatment of pain and endotoxaemia with flunixin meglumine will not influence the colonic recovery process. Therefore, the clinical strategy for the management of large colon injury should be aimed at preventing and treating the consequences of increased epithelial permeability including endotoxaemia.
The right dorsal colon is the shortest and widest section of the equine ascending colon. Like the ventral colon, it is sacculated and is a major site of fluid secretion and absorption (Argenzio et al. 1974b). In contrast to the ventral colon, a net secretion of fluid occurs in the dorsal colon (Argenzio et al. 1974b). Also, unlike the ventral colon, the right dorsal colon is well attached to the abdominal roof, caecal base and root of the mesentery. It is therefore not susceptible to volvulus and the resultant ischaemic injury. However, the administration of phenylbutazone, a nonselective COX inhibitor, has been shown to cause right dorsal colitis, which may result in death (McConnico et al. 2008). Experimental studies have shown that prolonged (21 days) administration of phenylbutazone decreases colonic volatile fatty acid production and mucosal blood flow (McConnico et al. 2008). While no study has examined the effect of prolonged phenylbutazone treatment on mucosal barrier function, the in vitro treatment of oxidant-injured right dorsal colon with phenylbutazone did not affect the recovery of barrier function (Rotting et al. 2004).
While studies of the effect of NSAIDs on the recovery of the colon from injury are limited, they do suggest that there may be significant differences in the response of the jejunal and colonic mucosal barrier to injury. As the colon is a physiologically complex organ, with varying functions throughout its length, further studies are required to determine the effect of injury location on the response to NSAID treatment. However, this may be difficult to assess in vitro as significant differences in the absorptive function have been identified when compared to the in vivo situation.